These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 32852645)

  • 41. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-based design and analysis of MAO-B inhibitors for Parkinson's disease: using in silico approaches.
    Kare P; Bhat J; Sobhia ME
    Mol Divers; 2013 Feb; 17(1):111-22. PubMed ID: 23325357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological and clinical implications of MAO-B inhibitors.
    Yu PH
    Gen Pharmacol; 1994 Dec; 25(8):1527-39. PubMed ID: 7721026
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An updated patent review on monoamine oxidase (MAO) inhibitors.
    Guglielmi P; Carradori S; D'Agostino I; Campestre C; Petzer JP
    Expert Opin Ther Pat; 2022 Aug; 32(8):849-883. PubMed ID: 35638744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthetic and Natural Monoamine Oxidase Inhibitors as Potential Lead Compounds for Effective Therapeutics.
    Pathak A; Srivastava AK; Singour PK; Gouda P
    Cent Nerv Syst Agents Med Chem; 2016; 16(2):81-97. PubMed ID: 26104056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biochemical characterization of the active site of brain monoamine oxidase.
    Youdim MB
    Monogr Neural Sci; 1980; 7():176-92. PubMed ID: 6785574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors.
    Deftereos SN; Dodou E; Andronis C; Persidis A
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):413-25. PubMed ID: 22943121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drugs related to monoamine oxidase activity.
    Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():112-24. PubMed ID: 26944656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The current status of monoamine oxidase and its inhibitors.
    Jarrott B; Vajda FJ
    Med J Aust; 1987 Jun; 146(12):634-8. PubMed ID: 3114597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parkinson's disease management. Part II- discovery of MAO-B inhibitors based on nitrogen heterocycles and analogues.
    Reis J; Encarnação I; Gaspar A; Morales A; Milhazes N; Borges F
    Curr Top Med Chem; 2012; 12(20):2116-30. PubMed ID: 23231391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.
    Binda C; Milczek EM; Bonivento D; Wang J; Mattevi A; Edmondson DE
    Curr Top Med Chem; 2011 Nov; 11(22):2788-96. PubMed ID: 22039878
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
    Naoi M; Maruyama W; Shamoto-Nagai M
    J Neural Transm (Vienna); 2018 Nov; 125(11):1635-1650. PubMed ID: 29279995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Concise Review of the Recent Structural Explorations of Chromones as MAO-B Inhibitors: Update from 2017 to 2023.
    Ipe RS; Kumar S; Benny F; Jayan J; Manoharan A; Sudevan ST; George G; Gahtori P; Kim H; Mathew B
    Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived
    Lee HW; Choi H; Nam SJ; Fenical W; Kim H
    J Microbiol Biotechnol; 2017 Apr; 27(4):785-790. PubMed ID: 28068665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee.
    Herraiz T; Chaparro C
    Life Sci; 2006 Jan; 78(8):795-802. PubMed ID: 16139309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular aspects of monoamine oxidase B.
    Ramsay RR
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():81-9. PubMed ID: 26891670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.
    Valente S; Tomassi S; Tempera G; Saccoccio S; Agostinelli E; Mai A
    J Med Chem; 2011 Dec; 54(23):8228-32. PubMed ID: 22017497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design, synthesis, and evaluation of N-methyl-propargylamine derivates as isoform-selective monoamine oxidases inhibitors for the treatment of nervous system diseases.
    Zhang K; Liu Y; Jia H; Wang H; Deng M; Liu Y; Zhao X; Xiu X; Li Z; Yang H; Cheng M
    Bioorg Chem; 2023 May; 134():106441. PubMed ID: 36854233
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives.
    Legoabe LJ; Petzer A; Petzer JP
    Eur J Med Chem; 2012 Mar; 49():343-53. PubMed ID: 22309913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.